Anti-β-glucan antibodies in healthy human subjects

Vaccine

Volumn 27, Issue 4, 2009, Pages 513-519

  Chiani, P ^a   Bromuro, C ^a   Cassone, A ^a   Torosantucci, A ^a  

^a Parasitic and Immune mediated Diseases   (Italy)

Author keywords

Glucan; Antifungal vaccine; Laminarin

Indexed keywords

BETA GLUCAN; FUNGUS ANTIBODY; FUNGUS ANTIGEN; FUNGUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN M; IMMUNOGLOBULIN SUBCLASS; LAMINARAN; MANNAN; POOL 1 ANTIGEN; PUSTULAN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CANDIDA ALBICANS; FEMALE; HUMAN; MALE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTIBODIES, FUNGAL; ANTIGENS, FUNGAL; BETA-GLUCANS; CANDIDA ALBICANS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MANNANS; MIDDLE AGED; YOUNG ADULT;

EID: 57749189800     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.030     Document Type: Article

References (27)

1. Cutler J.E., Deepe Jr. G.S., and Klein B.S. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 5 1 (2007) 13-28
2. Cassone A. Fungal vaccines: real progress from real challenges. Lancet Infect Dis 8 2 (2008) 114-124
3. Casadevall A., Dadachova E., and Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2 9 (2004) 695-703
4. Pachl J., Svoboda P., Jacobs F., Vandewoude K., van der Hoven B., Spronk P., et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42 10 (2006) 1404-1413
5. Spellberg B., Ibrahim A.S., Yeaman M.R., Lin L., Fu Y., Avanesian V., et al. The anti-fungal rAls3p-N vaccine protects mice against the bacterium Staphylococcus aureus. Infect Immun 76 10 (2008) 4574-4580
6. Cassone A., and Torosantucci A. Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. Expert Rev Vaccines 5 6 (2006) 859-867
7. Torosantucci A., Bromuro C., Chiani P., De Bernardis F., Berti F., Galli C., et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202 5 (2005) 597-606
8. Rachini A., Pietrella D., Lupo P., Torosantucci A., Chiani P., Bromuro C., et al. An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect Immun 75 11 (2007) 5085-5094
9. Masuoka J. Surface glycans of Candida albicans and other pathogenic fungi: physiological roles, clinical uses, and experimental challenges. Clin Microbiol Rev 17 2 (2004) 281-310
10. Klis F.M., de Groot P., and Hellingwerf K. Molecular organization of the cell wall of Candida albicans. Med Mycol 39 Suppl 1 (2001) 1-8
11. Brown G.D., and Gordon S. Immune recognition of fungal beta-glucans. Cell Microbiol 7 4 (2005) 471-479
12. Read S.M., Currie G., and Bacic A. Analysis of the structural heterogeneity of laminarin by electrospray-ionisation-mass spectrometry. Carbohydr Res 281 2 (1996) 187-201
13. Ishibashi K., Yoshida M., Nakabayashi I., Shinohara H., Miura N.N., Adachi Y., et al. Role of anti-beta-glucan antibody in host defense against fungi. FEMS Immunol Med Microbiol 44 1 (2005) 99-109
14. Kondori N., Edebo L., and Mattsby-Baltzer I. Candida albicans cell wall antigens for serological diagnosis of candidemia. Med Mycol 41 1 (2003) 21-30
15. Keller R.G., Pfrommer G.S., and Kozel T.R. Occurrences, specificities, and functions of ubiquitous antibodies in human serum that are reactive with the Cryptococcus neoformans cell wall. Infect Immun 62 1 (1994) 215-220
16. Iorio E., Torosantucci A., Bromuro C., Chiani P., Ferretti A., Giannini M., et al. Candida albicans cell wall comprises a branched beta-d-(1 → 6)-glucan with beta-d-(1 → 3)-side chains. Carbohydr Res 343 6 (2008) 1050-1061
17. Torosantucci A., Bromuro C., Gomez M.J., Ausiello C.M., Urbani F., and Cassone A. Identification of a 65-kDa mannoprotein as a main target of human cell-mediated immune response to Candida albicans. J Infect Dis 168 2 (1993) 427-435
18. Bromuro C., Torosantucci A., Chiani P., Conti S., Polonelli L., and Cassone A. Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine. Infect Immun 70 10 (2002) 5462-5470
19. Torres M., and Casadevall A. The immunoglobulin constant region contributes to affinity and specificity. Trends Immunol 29 2 (2008) 91-97
20. Han Y., Morrison R.P., and Cutler J.E. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 66 12 (1998) 5771-5776
21. Dotan I., Fishman S., Dgani Y., Schwartz M., Karban A., Lerner A., et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131 2 (2006) 366-378
22. Sturtevant J., and Calderone R. Candida albicans adhesins: biochemical aspects and virulence. Rev Iberoam Micol 14 3 (1997) 90-97
23. Cutler J.E. Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 5 4 (2005) 383-392
24. Cassone A., De Bernardis F., and Torososantucci A. An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr Mol Med 5 4 (2005) 377-382
25. Fattom A. Qualitative and quantitative immune response to bacterial capsular polysaccharides and their conjugates in mouse and man. Adv Exp Med Biol 383 (1995) 131-139
26. Ravetch J.V., and Kinet J.P. Fc receptors. Annu Rev Immunol 9 (1991) 457-492
27. Weinberg G.A., Granoff D.M., Nahm M.H., and Shackelford P.G. Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of Haemophilus influenzae. J Immunol 136 11 (1986) 4232-4236